For a better experience, click the Compatibility Mode icon above to turn off Compatibility Mode, which is only for viewing older websites.


  • Medical Device Startup Nephria Bio to Use Drexel's MXene Filter Material in Wearable Artificial Kidney Technology

    April 29, 2021

    <p style="margin: 0in;">Drexel University&rsquo;s MXene material is one step closer to transforming the lives of people suffering from end-stage kidney disease. Nephria Bio, Inc., a U.S.-based spin-off of the South Korean medical device company EOFlow Co., Ltd., has signed a licensing agreement with the University to use the two-dimensional material, discovered at Drexel, as a filter in a wearable artificial kidney device it is developing. The technology could allow many of the millions of people suffering from end-stage kidney disease worldwide to move more freely, without spending hours each week anchored to large dialysis machines.</p>
    <p style="margin: 0in;">&nbsp;</p>

    Read More

  • Rain Therapeutics Announces Pricing of Initial Public Offering

    April 22, 2021

    Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the pricing of its initial public offering of 7,352,941 shares of common stock at a public offering price of $17.00 per share. The gross proceeds to Rain from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Rain, are expected to be approximately $125.0 million. All of the shares are being offered by Rain. The shares are expected to begin trading on The Nasdaq Global Select Market on April 23, 2021 under the ticker symbol “RAIN.” In addition, Rain has granted the underwriters a 30-day option to purchase up to an additional 1,102,941 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on April 27, 2021 subject to the satisfaction of customary closing conditions.

    Read More